Ashvattha Therapeutics, Inc. is thrilled to announce the successful closing of a $50 million funding round, a significant milestone that propels our mission to revolutionize precision medicine. Leveraging our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from the esteemed Johns Hopkins University, we are pioneering a new class of drugs designed to identify and treat diseased cells with unmatched precision. Our innovative approach enables the development of hydroxyl dendrimer therapeutics (HDTs), which intricately link established small molecule drugs to hydroxyl dendrimers, facilitating selective delivery and prolonged therapeutic effects directly within diseased tissues. This strategic funding will accelerate our research and development initiatives, allowing us to further advance our pipeline, specifically targeting critical areas such as neurology, ophthalmology, hyperinflammatory diseases, and neuro-oncology. With this financial backing, Ashvattha Therapeutics is committed to transforming the standard of care for patients suffering from these debilitating conditions. We are excited about the potential impact our therapies may have, not only on individual lives but also on broader public health outcomes. The support from our investors reaffirms the confidence in our pioneering vision and technology, and we look forward to translating our innovative research into tangible results that will enhance treatment efficacy and patient quality of life. This landmark funding is not just an investment in Ashvattha Therapeutics; it is an investment in the future of medicine.
Precision Medicine Pioneer Ashvattha Therapeutics Secures $50M in Funding for Groundbreaking Drug Development
Recently funded 路 $50.0MBiopharmaceutical
Get the full Ashvattha Therapeutics, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
